

# Eliquis - (2.5, 5 mg; Tablet, Oral)

| Generic Name          | Apixaban   | Innovator            | BRISTOL MYERS SQUIBB |
|-----------------------|--|----------------------|----------------------|
| Dosage                | 2.5, 5 mg; Tablet, Oral  | Branded US Sales     | More Than \$1000 mn  |
| Probable FTF          | More Than 5  | Known Para IV Filers | More Than 5          |
| Other ANDA developers | More Than 5  | Tentative Approvals  | More Than 5          |
| Final Approvals       | More Than 5  | Generic Launches     | None                 |
| Indication            | Used to reduce risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). Prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients who have undergone hip or knee replacement surgery. Treatment of DVT or PE |                      |                      |
| Complexities          | Yes  |                      |                      |

## **Chronology Of Events**

Please Contact contact@researchdelta.com to get Detailed Information.

## **Executive Summary**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.

#### **Patent Status**

Please Contact  $\underline{contact@researchdelta.com}$  to get Detailed Information.

### **Launch Timelines and Competition**

Please Contact  $\underline{contact@researchdelta.com}$  to get Detailed Information.

# **Chronology Of Events**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.